Last reviewed · How we verify
Synvisc-One
Synvisc-One is a hyaluronic acid-based viscosupplement that lubricates and cushions the knee joint to reduce pain and improve mobility in osteoarthritis.
Synvisc-One is a hyaluronic acid-based viscosupplement that lubricates and cushions the knee joint to reduce pain and improve mobility in osteoarthritis. Used for Osteoarthritis of the knee.
At a glance
| Generic name | Synvisc-One |
|---|---|
| Also known as | Active Comparator, GZ402662; hylan G-F 20 |
| Sponsor | Nature Cell Co. Ltd. |
| Drug class | Viscosupplement; hyaluronic acid derivative |
| Target | Synovial fluid; joint cartilage surfaces |
| Modality | Small molecule |
| Therapeutic area | Orthopedics; Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Synvisc-One is a single-injection formulation of hylan G-F 20, a viscoelastic fluid derived from hyaluronic acid. It works by restoring the viscosity and elasticity of synovial fluid in the knee joint, thereby reducing friction between cartilage surfaces and providing shock absorption. This mechanical lubrication and cushioning effect alleviates pain and improves joint function in patients with knee osteoarthritis.
Approved indications
- Osteoarthritis of the knee
Common side effects
- Injection site pain or swelling
- Transient knee effusion
- Knee stiffness
Key clinical trials
- Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee Osteoarthritis (NA)
- A Study to Evaluate the Efficacy, Safety and Tolerability of EVI-01 Intra-Articular Injection in Osteoarthritis of the Knee (NA)
- Comparison of Single Intra-articular Injection of Hyruan-One With Hylan G-F 20 in Knee Osteoarthritis (PHASE4)
- Evaluation of Treatment of Osteoarthritis of the Knee in the Form of Chondromalacia of the Articular Cartilage Treated in the Arthroscopic Technique With the Use of:Autogenous Transplantation of Fragmented Adipose Tissue,PRP GF,Mesenchymal Cells,Hyaluronic Acid-low Molecular Weight and Cross-linked (NA)
- Performance of CCoat Intra-Articular Injections in Mild to Moderate Knee Osteoarthritis: A Prospective, Randomized, Double-Blind, Multi-center Trial (NA)
- New Treatment of Knee Osteoarthritis (NA)
- nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis (NA)
- Treatment of Knee Osteoarthritis With PAAG-OA (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |